Business Context and Reporting Period
This Form 8-K Current Report was filed by Karyopharm Therapeutics Inc. on August 25, 2020, with the earliest event reported on that date. The filing primarily addresses Item 5.02 regarding modifications to compensatory arrangements for certain officers and the election of a new director.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and executive compensation adjustments.
Material Changes
Executive Compensation Modifications
On August 25, 2020, the Compensation Committee approved enhanced severance and benefit packages for four key executives, effective via agreements dated August 31, 2020:
- Dr. Kauffman: Severance increased to 18 months of base salary (from 12) and 18 months of COBRA coverage (from 12) for termination without cause or good reason prior to a change of control. Added a 150% target bonus payment for termination after a change of control.
- Dr. Shacham: Severance increased to 18 months of base salary (from 9) and 18 months of COBRA coverage (from 9) prior to a change of control. Post-change of control, severance is 18 months of salary (from 12), 18 months of COBRA (from 12), and a 150% target bonus payment.
- Mr. Primiano: Severance increased to 12 months of base salary (from 6) and 12 months of COBRA coverage (from 6) prior to a change of control. Added a 100% target bonus payment for termination within one year following a change of control.
- Mr. Mason: Severance increased to 12 months of base salary (from 6) and 12 months of COBRA coverage (from 6) prior to a change of control. Added a 100% target bonus payment for termination within one year following a change of control.
Election of Director
On August 28, 2020, the Board elected Christy J. Oliger as a director and appointed her to the Compensation Committee. The Board size increased from seven to eight members. Ms. Oliger received:
- An annual cash retainer of $50,000 for Board service and $7,500 for Compensation Committee service (prorated).
- An option to purchase 32,800 shares of common stock, vesting over three years.
- Standard indemnification coverage.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on business outlook, or discussion of specific risks or contingencies beyond the standard disclosure that the compensation modifications are subject to the full text of the filed agreements.
Investor Verification Checklist
- Review Exhibits 10.1 through 10.4 for the full legal terms of the amended executive compensation agreements.
- Verify the impact of the increased severance liabilities on the company's future cash flow obligations in the event of executive departures.
- Confirm the vesting schedule and exercise price of the 32,800 stock options granted to the new director, Ms. Oliger.
- Check subsequent filings for any changes to the Board composition or executive roles following these appointments.